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Cardiovascular diseases, particularly acute myocardial infarction, are the leading causes of death worldwide. Important advances
have been made in the secondary treatment for cardiovascular diseases such as heart transplantation and medical and surgical
therapies. Although these therapies alleviate symptoms, and may even improve survival, none can reverse the disease process and
directlyrepairthelastingdamage.Thus,thecureofcardiovasculardiseasesremainsamajorunmetmedicalneed.Recently,cellular
therapy has been proposed as a candidate treatment for this. Many stem and progenitor cell populations have each been suggested
as a potential basis for such therapy. This review assesses some of the more notable exogenous adult cell candidates and provides
insights into the mechanisms by which they may mediate improvement in cardiac function following acute myocardial infarction.
Researchintothecellulartherapyﬁeldisofgreatimportanceforthefurtherplanningofclinicaltrialsforcardiaccellularmyoplasty.
Copyright © 2009 Matthew M. Cook et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Cardiovascular disease (CVD) is a broad term referring to
all diseases that involve the heart and/or blood vessels. CVD
is the leading cause of death worldwide, estimated at causing
17.5milliondeathsin2005.Oftheseanestimated7.6million
were due to ischaemic heart disease (IHD) which is a subset
ofCVDandischaracterisedbyocclusionofacoronaryartery
causing decreased blood ﬂow and deprivation of oxygen
and nutrients to the high energy-requiring cardiomyocytes
in the myocardium [1]. This situation is also known as
acute myocardial infarction (AMI) or more commonly a
heart attack. While this may be an acute or transient
condition (i.e., the heart is reperfused after a temporary
occlusion), the ischemic damage due to loss of blood ﬂow
causes signiﬁcant cardiomyocyte death and the subsequent
irreversible formation of a ﬁbrotic scar [2]. This, in turn,
leads to dyskinesis of the ventricular wall, diminished heart
function, and chronic heart failure (CHF).
Within the last 10–15 years, pharmaceutical thera-
pies (aspirin, angiotensin converting enzyme-inhibitors, β-
blockers), percutaneous coronary interventions, coronary
artery bypass graft surgery, left ventricular assist devices
and biventricular pacing have made a signiﬁcant impact on
the cardiovascular disease burden. Heart transplantation is
also well established, but the need for long-term immune
suppression and the chronic donor organ shortages suggest
that it is unlikely to evolve into a viable deﬁnitive treatment
for the majority of persons with cardiac disease. Although
these therapies ameliorate symptoms, and may even improve
survival, none can claim to directly reverse the disease
process itself.
With recent advances in medicine and associated tech-
nologies, a number of novel therapies for the repair of the
myocardium following ischaemia have been suggested. The
most prominent of these is the use of cells to repair existing
cardiac damage with bone marrow being the commonest
source due to its readily accessible nature and autologous
sourcing. Bone marrow mononuclear cells (BMCs), periph-
eral blood stem cells (PBSCs), mesenchymal stem cells
(MSCs), and endothelial progenitor cells (EPCs) have been
investigated in animal and human studies. However, many
of these cell populations have been incompletely charac-
terised and are thought to be a mixture of several related2 International Journal of Cell Biology
subpopulations. At present, BMCs are the most common
source for cell-based therapy and, due to the 40 years of
experience with bone marrow transplants used for treating
haematological diseases, they have rapidly been applied to
clinical trials in severe cardiac disease. Although the ﬁrst
phase I/II controlled clinical trials using BMCs to improve
cardiac function after AMI were recently published (with
variable results) [3, 4], it is still unclear as to which bone
marrow cell population contributed to the repair of cardiac
muscle damaged by ischaemia in these trials. This review
will clarify the potential of puriﬁed adult cell populations to
repair the damaged myocardium and outline several possible
mechanisms of repair.
2. Stem/Progenitor Cell Populations
Stem cells are deﬁned by two key characteristics. Firstly, they
must be able to self-renew in that they can go through many
cell division cycles whilst remaining in an unchanged and
undiﬀerentiated state. Their second property is the capacity
to diﬀerentiate into multiple specialised cell types [5], and
the potency of stem cells is often deﬁned by their potential
to diﬀerentiate. At one end of the spectrum stem cells
a r ea b l et od i ﬀerentiate into specialised mature cells from
all three germ layers. These are termed pluripotent stem
cells with embryonic stem cells (derived from blastocyst of
a developing embryo) as the prime example. Alternately,
multipotent stem cells are restricted to diﬀerentiating into
certain closely related lineages often of the same germ
layer [5, 6]. Adult (or somatic) stem cells are derived from
postnatal or mature tissues and are primarily multipotent.
However, some subsets have shown plasticity across multiple
germ layers [7, 8]. Some adult stem cells have a limited
capacity for self-renewal and may thus be better classiﬁed
as adult progenitor cells. Although progenitor cells are
also deﬁned by the properties of self-renewal and multi-
potency, these are observed to a lesser extent compared
to pluripotent stem cells. Hence, progenitor cells are more
committed to speciﬁc lineage diﬀerentiation than stem cells
(Figure 1).
2.1. Mesenchymal Stem Cells (MSCs). MSCs were ﬁrst
recognised by Friedenstein et al., who identiﬁed a plastic
adherent, ﬁbroblast-like population (Figure 2) that could
regenerate rudiments of normal bone in vivo [9–11]. MSCs
were initially identiﬁed within the stroma of the bone
marrow and were subsequently found to provide support
for haematopoiesis by secreting many colony-stimulating
factors and growth factors important in the proliferation,
diﬀerentiation and survival of haematopoietic cells [12–15].
Although a majority of the literature is concerned with
bone marrow derived MSCs, they have also, in more recent
times, been isolated from other organs including placenta,
adipose, cord-blood, and liver [8, 16–21]. Recently, they have
been shown to be ubiquitous since they have been shown
to be an integral part of the composition of endothelium
(perivascular cells or pericytes) [22, 23].
Although no single marker speciﬁc for MSCs has yet
beendescribed,theyarecharacteristicallynegativefortypical
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Figure 1: Diﬀerentiation and self-renewal potential of embryonic
stem cells, adult stem cells, and progenitor cells.
haematopoietic lineage antigens such as CD45, CD34, and
CD14 and positive for CD44, CD73, CD90, CD105, CD166,
and Stro-1 [24–29]. MSCs also produce a large number of
growth factors and cytokines, including vascular endothelial
growthfactor(VEGF) [13].ThissuggestsMSCsinvolvement
in paracrine mechanisms. However, the current hallmark
for MSCs is their ability to diﬀerentiate into mature cell
populations of the mesodermal lineage such as bone, car-
tilage, tendon, muscle, and adipose tissue [25, 28, 30, 31].
Interestingly, some groups have also shown MSCs to have
plasticity beyond the mesodermal lineage with the ability to
diﬀerentiateintoneuronsandastrocytes(ectodermal)aswell
as hepatocytes (endodermal) [7, 8].
MSCs also appear to have a signiﬁcant advantage for
cell therapy in that they are immunologically privileged
and even in large outbred animals can be transplanted
across major histocompatibility (MHC) barriers without the
need for immune suppression [32–34]. This has important
implications in that MSCs can be taken from a healthy
unrelated donor and cryopreserved ready for use in patients
with a wide variety of pathologies [35]. In addition to
this relative lack of immunogenicity, MSCs are actively
suppressive of T cell function [36, 37]. This immune
suppressive capability has been successfully exploited in the
clinic where unrelated, MHC-unmatched or mismatched
MSCs have been used to treat patients with acute graft-
versus-host disease (GVHD) [33, 38, 39].
MSCs show promise as a cellular therapeutic agent due
to their ease of expansion, immuno-privileged status, and
ability to self-renew and to diﬀerentiate across multiple
mature cell lineages. Because of their multipotency, they
have been investigated in cardiovascular disease [40, 41],
neurological disease [42], osteogenesis imperfecta [43–45],
osteoarthritis [46], GVHD [33, 39], and liver ﬁbrosis [47].
Controversially, MSCs have been induced to diﬀerentiate
into cardiomyocytes in mice [48] and humans [41], and
several studies have shown improved myocardial function
after myocardial ischaemia in rodents and pigs [40, 41].
This indicates their potential for treatment of damage causedInternational Journal of Cell Biology 3
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Figure 2: Mesenchymal stem cell morphology by light microscopy. (a) MSCs culture (×100), (b) Cytospin and Giemsa stained (×1000).
by ischemic myocardial infarction in human. Finally, there
are some reports that MSCs migrate preferentially to sites
of inﬂammation as opposed to the bone marrow, as has
been reported in some studies to be the case in unperturbed
animals [26, 28].
2.2. Haematopoietic Stem/Progenitor Cells (HSCs/HPCs).
HSCs/HPCs are the best characterised adult stem cell and
are the only stem or progenitor cells that are in routine
clinical use today. HSCs normally reside in the bone marrow
and are responsible for making all blood cell types and thus
continually reconstituting the haematopoietic and immune
systems [49, 50]. These cells are used clinically in bone
marrow transplants to treat a number of blood disorders
including leukaemia, aplastic anaemia, and severe combined
immunodeﬁciency [51, 52]. The functional hallmark of a
true HSCs is the in vivo ability to reconstitute all blood
lineages (from a single cell) following otherwise lethal total
body irradiation (TBI).
In the human, HSCs/HPCs are identiﬁed by cell surface
expression of CD34, a cell surface glycoprotein [49, 53, 54].
However,isolationofCD34+ cellsfromumbilicalcordblood,
bone marrow, or peripheral blood aphaeresis product leads
to a relatively heterogeneous population, while true HSCs,
as deﬁned by single-cell repopulation capacity, represent
less then 0.1% of CD34+ enriched cells [55]. Thus, a
CD34 enriched population is often referred to as an HPC
population containing lineage-committed cells as well as
HSCs. Although CD34 is also expressed in the mouse, the
regulation of the CD34 gene is diﬀerent to that in the human
[53]. Thus, it is not a reliable HPC marker in the mouse.
Furthermore, it has been shown that CD34
−/low murine
HSCs can reconstitute the haematopoietic system following
TBI [54].
Murine studies of HSCs often use the following mark-
ers: c-kit+, CD45+, and lineage−/low. Lineage−/low status is
commonly deﬁned as negativity for CD5 (T cells), CD11b
(myeloid cells), CD45R (B cells), Gr-1 (granulocytes), and
Ter119 (erythrocytes). This population can be further puri-
ﬁed with the addition of the Sca-1+ marker to the panel
and these HSCs are termed LSK cells (Lineage/Sca-1/c-kit)
(Figure 3). However, these cells still represent a heteroge-
neous population with approximately one in ten having
the ability to repopulate the haematopoietic system [56].
More recently, the signal lymphocyte activating molecule
(SLAM) receptors (CD48, CD150, and CD244) have been
used to further enrich the LSK population to derive a more
primitive HSC population [57–59]. In humans, earlier HSCs
are identiﬁed by the phenotypes CD34+ CD90+ or CD34+
CD38
− [60].
HPCs migrate preferentially to the bone marrow in
healthy animals and the molecular mechanisms of this
migration are well described, including rolling and tethering
of HPCs on bone marrow endothelium, followed by their
arrestandﬁrmadhesiontotheendothelium[61–63].Itisnot
known if intravenously injected HPCs migrate preferentially
to acutely inﬂamed tissue.
Itisdebatedastowhetherbonemarrowcellsenrichedfor
HPCs participate in the repair of cardiomyocytes following
infarction. Orlic et al. (2001) and Rota et al. (2007) have
shown that bone marrow cells enriched for c-kit are capable
of diﬀerentiating into cardiomyocytes [64, 65]. However,
these c-kit+ enriched populations were heterogeneous and
may have contained stromal cell populations. Furthermore,
HPCs have been observed to diﬀerentiate into skeletal
muscle ﬁbres during muscle regeneration [66]. Conversely,
it has also been shown that HPCs do not diﬀerentiate
into cardiomyocytes following infarction and rather take
on a mature haematopoietic fate which may, in turn, give
rise to diﬀerentiated haematopoietic cells, responsible for
the inﬂammatory wound healing process [67, 68]. Various
other actions of HPCs on injured tissue have been proposed
including secretion of cytokines and chemokines, inhibition
of apoptosis, and suppression of immune reactions [69, 70].
2.3. Endothelial Progenitor Cells (EPCs). Historically, neoan-
giogenesis (the formation of new blood vessels) was thought
to occur by the proliferation of existing endothelial cells.
However, in 1997 Asahara et al. discovered “putative pro-
genitor endothelial cells” in adult peripheral blood [71]. In4 International Journal of Cell Biology
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Figure 3: Morphology of (a) haematopoietic progenitor cells displaying a heterogeneous morphology and (b) the more puriﬁed LSK
showing a more homogeneous morphology (light microscopy ×1000).
the last 10 years, this discovery has been conﬁrmed and
it is now commonly accepted that EPCs play an essential
role in adult blood vessel formation, endothelial repair,
and endothelial homeostasis [72, 73]. These postnatal cells
have been extensively explored for their innate capacity
to contribute to angiogenesis in both pathological and
unperturbed states. Like MSCs and HPCs, EPCs can also be
derived from the bone marrow. They circulate in peripheral
blood in a very low numbers, but can be mobilised into
the blood using molecules such as granulocyte colony-
stimulating factor (G-CSF) [74].
EPCs derived from adult human peripheral blood were
initially characterised by expression of both CD34+ and
Flk-1+ [71]. Flk-1 is also known as vascular endothelial
growth factor receptor (VEGFR)-2 in mice and kinase insert
domain receptor (KDR) in humans. Along with vascular
endothelial growth factor receptor-1 (VEGFR-1, also known
as Flt-1), VEGFR-2 serves to mediate the actions of VEGF,
which is recognised as an essential regulator of angiogenesis
[74, 75]. VEGFR-2 expression is considered to be a marker of
progenitor cell commitment to the endothelial lineage and
is now typically used in conjunction with other antigens,
such as vascular-endothelium (VE)-cadherin (CD144) and
CD31 (also known as platelet/endothelial cell adhesion
molecule-1 or PECAM-1) to identify putative angioblasts or
EPCs [76, 77]. Another key marker is CD133 (prominin-
1) and, like CD34, it is present on both HPCs and cells
that exhibit a potent blood-vessel forming capacity [78,
79]. In the developing embryo, EPCs and HSCs arise from
a common precursor called the haemangioblast [80, 81].
Hence, a majority of markers used to identify EPCs are also
prevalent on haematopoietic progenitors. Although these
markers prove useful in identifying populations enriched for
the angioblast or EPCs, it should be recognised that deﬁning
hierarchical relationships is far from currently agreed upon
[77, 82].
It is now more common for EPCs to be isolated from
peripheral blood, bone marrow, or umbilical cord blood
(UCB) based on their morphologic and adherent charac-
teristics when cultured on ﬁbronectin or collagen-coated
plates in the presence of appropriate growth media and sup-
plemental angiogenic diﬀerentiation factors. These factors
include VEGF, ﬁbroblast growth factor-2 (FGF-2), insulin-
like growth factor-1 (IGF-1), and epidermal growth factor
(EGF) [75, 76, 83, 84]. The majority of cells that appear in
early stages of culture (within the ﬁrst 15 days) are thought
to have originated from a CD14+ (macrophage/monocyte)
subpopulation of mononuclear cells. These cells are often
referred to as early-outgrowth endothelial progenitor cells
(EO-EPCs) [75, 83, 85]. Conversely, late-outgrowth EPCs
(LO-EPCs) do not appear in culture for 2-3 weeks and
exhibit the “classic endothelial” phenotype with contact
inhibition and cobblestone monolayer morphology and the
ability to form in vitro tube-like structures when seeded on
Matrigel (Figure 4). These LO-EPCs also show exponential
growth kinetics and a capacity for ex vivo expansion [75, 77,
83, 85, 86].
It has been extensively shown that EPCs are associated
with neoangiogenesis following tissue injury in animal
models of hind-limb ischaemia and myocardial infarction
[4, 84, 87, 88]. Conversely, however, administration of EPCs
into human patients with CVD is yet to show eﬃcacy with
regard to vessel formation, even though these patients had
a better clinical outcome [89]. This observation suggests
that improvement may have been due to, at least in part, a
paracrine function.
2.4. Non-Stem/Progenitor Cell Populations. It is well estab-
lished that monocytes/macrophages play an important role
in angiogenesis, ﬁrst shown in 1977 [90]. This occurs by
the release of tumour necrosis factor-α (TNF-α), throm-
bospondin, and angiogenic factors such as VEGF, angiopoi-
etin, and matrix metalloproteinases (MMPs) [91–93]. Cells
of the macrophage lineage play a major role in the innate
immune response and contribute to wound healing, tissue
repair, and bone remodeling [94]. Any disturbance of
tissue normality such as infection, aberrant cell turnover,
or tissue damage leads to an inﬂammatory response and
a rapid recruitment of macrophages. During inﬂammation
monocytes and macrophages phagocytose foreign particlesInternational Journal of Cell Biology 5
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Figure 4: Endothelial progenitor cells derived from human umbilical cord blood (a) exhibit classic cobble-stone morphology (light
microscopy ×40) and (b) form tube-like structures when seeded on Matrigel basement membrane matrix (light microscopy ×100).
(cellular debris or pathogens) and stimulate lymphocytes
and other immune cells to respond to the pathogen by
release of a variety of cytokines and chemoattractants that
can modulate the migration of circulating cells and their
adhesion to local endothelial cells [2, 91, 93, 95].
A novel lineage of monocytes has recently been isolated
that is thought to play a key role in the revascularisation
process. These cells are isolated from mice as CD11b
+ mono-
cytes (or from human as CD14+ and CD16
−)a n de x p r e s s
the angiogenic marker Tie-2 (tunica internal endothelial
cell kinase-2) [96–99]. Tie-2 is a receptor tyrosine kinase
expressed principally on vascular endothelium and is also
expressedonHPCsandEPCs.Itsligandsaretheangiopoietin
growth factors that promote the growth of new blood vessels
and are involved with migration of Tie-2-expressing cells to
sites of inﬂammation [96–98]. Tie-2 has also been hypoth-
esised to be involved in the attenuation of proinﬂammatory
mediators.
Tie-2 expressing monocytes (TEMs) have been isolated
from the bone marrow of mice by plastic adherence and
stimulation with macrophage colony-stimulating factor (M-
CSF or CSF-1). These cells have a large nucleus surrounded
by a cytoplasm with an abundance of vacuoles (Figure 5).
They have also been identiﬁed in the peripheral blood of
mice [96] and from human PBMCs [98, 99]. However, the
literatureonthissubjecthasbeenfocusedonhowTEMsmay
contribute to tumour-associated angiogenesis and thus these
cells have often been identiﬁed and isolated from various
mouse and human tumours. It is thought that TEMs may
contribute to tumour angiogenesis by providing paracrine
support to nascent blood vessels and by the sequestering of
endothelial cells. TEMs produce proangiogenic factors and,
when injected in Matrigel matrix plugs implanted under
the skin of rodents, promote robust angiogenesis whilst not
forming new blood vessels themselves. These data suggest
that their recruitment to the site of ischaemic injury is
suﬃcient to support revascularisation [96, 98, 100].
Monocytes are attracted to the myocardium by over-
expression of monocyte chemoattractant protein-1 (MCP-
1), where there is evidence that they form CD31-negative
(PECAM) tunnels. Monocytes and macrophages “drill tun-
nels” using matrix metalloproteinases (MMPs). However
it is yet to be demonstrated whether these become new
vessels [100–102]. It has been proposed that neoangiogenesis
occurs via the contribution of monocytes, macrophages, and
circulating EPCs.
3.Possible Mechanismsof
TissueRepairby Cells
3.1. Diﬀerentiation into Cardiomyocytes and Cell Fusion.
Stem cells may have the potential to replace necrotic
myocardium, form new cardiomyocytes, and restore cardiac
function after AMI [5, 103]. Cardiomyocyte diﬀerentiation
in vitro has been shown with embryonic stem cells [104],
HPCs [64, 65], MSCs [41], and EPCs [105]. Few studies,
however,havebeenabletoreplicatethisphenomenoninvivo
and signiﬁcant cell numbers have failed to diﬀerentiate in
the myocardium [67, 106]. Although these studies showed
a lack of physical repair of the myocardium, there was still,
in most cases, an improvement in cardiac function. These
data suggest that there may be other mechanisms mediating
functional improvement. One alternative to diﬀerentiation is
the occurrence of cell fusion to support cardiomyogenesis.
However, the occurrence of this is also rare [107–109].
3.2. Paracrine Function. Stem cells secrete many soluble
factors that may directly or indirectly have reparative qual-
ities. In cardiac ischaemia, these factors may signal through
pathways that act to promote angiogenesis, decrease apopto-
sis, increase the eﬃciency of cardiomyocyte metabolism, or
modulate inotrophy (formation of ﬁbrous scar) [2]. There
is evidence of bone marrow mononuclear cell-conditioned
media showing reparative features in preclinical models
of AMI [110–113]. This conditioned media contained a
variety of cytokines including VEGF, interleukin-1 (IL-1),
placental-derived growth factor (PDGF), IGF-1 and MCP-1.
It has also been shown that these factors were signiﬁcantly6 International Journal of Cell Biology
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Figure 5: Analysis of Tie-2 expressing monocytes by (a) culture morphology (light microscopy ×100) and (b) Giemsa staining (light
microscopy ×1000).
upregulated when the cells are cultured in a hypoxic state
[114]. Transfusion of this media led to increased capillary
density, decreased infarct size, and improvement of cardiac
function following myocardial infarction [110, 112]. Whilst
transfusion of the conditioned media is potentially seen as
a useful therapeutic agent, the need for the donor cells to
be transfused was still apparent as it was shown that some
functional reparative mechanisms only occurred when the
bone marrow derived cells were present. There is also a need
for such a pool of cytokines to be constantly replenished,
a function that can be performed by constant transfusion
of conditioned media or a single transfusion of a cellular
“cytokine factory”.
3.3. Vascular Remodeling. Interventions that increase the
perfusion to areas of restricted blood ﬂow may cause
salvage of border-zone cardiomyocytes as well as partial
reversal of pathological myocardial remodeling. Increased
vascularisation may occur via two pathways. Firstly, it
may occur by angiogenesis which is the formation of new
branches of blood vessels from pre-existing vessels and thus
an increase in perfusion. Secondly, it may occur by an
increase in diameter of existing vessels causing an increase
in local perfusion [104]. The success of both these events
is determined by the pre-existence of a vascular network,
activation of the endothelium by ﬂuid pressure stress,
invasion of bone marrow derived cells, and proliferation of
endothelial and smooth muscle cells [115]. Cell therapy may
act in a paracrine mechanism to increase the production of
proangiogeniccytokines(asmentionedabove)andstimulate
host cells to remodel the existing vasculature by either
forming new branches or converting an arteriole into an
artery. Alternately, donor cells may physically embed in the
ischaemic tissue and become new vessel branches.
Various studies have shown revascularisation in animal
models of hind-limb ischaemia and myocardial infarction
with EPCs [87, 116–118], HPCs [64, 66], BMCs [112, 119],
and MSCs [120]. One such study by Kocher et al. [81]
showed that human mobilised CD34+ cells homed to the
infarcted myocardium where they were incorporated into
newly developed coronary circulation. However, similar to
the diﬀerentiation process above, there is limited evidence
showing that the cells themselves are directly or physically
participating in this event [121]. This, once again, reinforces
the potential value of the paracrine function of infused cells
as they are often associated with an increase in capillary
density in the infarcted region.
3.4. Cardiac Protection. Donor cell secretion of numer-
ous cytokines is believed to attenuate the apoptotic
state. For example, IGF-1 [122], hepatocyte growth factor
(HGF) [123], and FGF [124] have all been shown to be
cardioprotective molecules by attenuation of cardiomyocyte
apoptosis.
Another form of cardiac protection is by modiﬁcation
of the immune response and this has subsequently been
acknowledged as a potential therapeutic target [104]. This
has been shown with MSCs, which suppress T-cell responses
and thus have local immunosuppressive functionalities [32,
39]. However, cardiac protection through these mechanisms
must be viewed with caution as many proinﬂammatory
and proapoptotic molecules are also involved in angiogenic
responses.
4. Conclusions
The ﬁeld of regenerative medicine is quickly evolving and
has been applied to many aspects of medicine including the
treatment of CVD. Cellular therapy has been proposed as a
candidate treatment for CVD. However, a majority of the
clinical studies have used mixed populations of cells. Thus,
it is still unclear as to which cell population contributed
to the repair of cardiac muscle damaged by ischaemia in
these trials. This review has outlined the characteristics of
some notable puriﬁed cell populations that can be used to
elucidate the possible roles and contributions of each cell
type. Each cell type has its own advantages and limitations
towards application for the treatment of CVD. This review
has also described the potential mechanisms by which these
cells mediate improvement in cardiac function following
myocardial infarction. Possible mechanisms of cardiac cel-
lular myoplasty include the generation of proangiogenicInternational Journal of Cell Biology 7
proteins,stimulationofnewbloodvesselformation,decrease
in apoptosis of cardiac cells, decrease in pathological cardiac
remodeling, diﬀerentiation into cardiomyocytes and cell
fusion. Taking into consideration the various mechanisms
of repair and the characteristics of each cell population, a
cocktail of speciﬁc cell types may need to be considered for
successful CVD cellular therapy.
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